Glofitamab is recommended, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B‑cell lymphoma in adults after 2 or more systemic treatments. Glofitamab is only recommended if the company provides it according to the commercial arrangement.
Why the committee made these recommendations
Treatment for relapsed or refractory diffuse large B‑cell lymphoma after 2 or more systemic treatments includes axicabtagene ciloleucel, polatuzumab vedotin with bendamustine plus rituximab, and rituximab-based chemotherapies.
Clinical trial evidence suggests that some people taking glofitamab reach complete remission, but in the trial, it was not compared with other treatments. Indirect comparisons suggest that glofitamab is likely to increase how long people live and how long people have before their condition gets worse, by:
as much as polatuzumab vedotin with bendamustine plus rituximab
more than bendamustine plus rituximab (which was used to represent all rituximab-based chemotherapies)
less than axicabtagene ciloleucel, but the results might favour axicabtagene ciloleucel because of the way the trial was designed.
The cost-effectiveness estimates are within the range that NICE normally considers an acceptable use of NHS resources. So, glofitamab is recommended.